FDA Approves Depemokimab for Severe Asthma: Eosinophilic Phenotype Treatment

Executive Brief

News Report

The News: FDA approves depemokimab for severe asthma treatment.
Clinical Win: New treatment option for eosinophilic phenotype asthma.
Target Specialty: Pulmonology

Key Data at a Glance

Approval Date: December 16, 2025
Clinical Trials Enrolled: 762 patients
Dosing Frequency: Once every six months

The FDA approved depemokimab (Exdensur) on December 16, 2025, for the add-on maintenance treatment of severe asthma characterized by an eosinophilic phenotype in patients aged 12 years and older. This approval is significant for healthcare providers as it offers a new therapeutic option for patients with uncontrolled asthma despite existing treatments.

Clinical Context

Asthma is a prevalent chronic respiratory condition affecting millions globally, characterized by airway inflammation and hyperreactivity, leading to symptoms such as wheezing, shortness of breath, and coughing. Severe asthma, particularly the eosinophilic phenotype, is often difficult to manage with standard therapies, including inhaled corticosteroids and other controller medications. Patients with this phenotype typically experience frequent exacerbations, which can significantly impair their quality of life and lead to increased healthcare utilization. Current treatment options may not adequately control symptoms, creating a need for novel therapies that can provide better management of this challenging condition. Depemokimab, a monoclonal antibody targeting IL-5, aims to reduce eosinophilic inflammation and improve asthma control in these patients, potentially leading to fewer exacerbations and better overall management of severe asthma.

Key Findings

The approval of depemokimab (Exdensur) is based on two pivotal clinical trials, SWIFT-1 and SWIFT-2, involving 762 patients with severe asthma that was not well controlled on their background therapy [1].

The trials demonstrated that depemokimab significantly reduced the annualized rate of asthma exacerbations compared to placebo, although specific numerical results were not disclosed in the summary [1].

Patients received depemokimab 100 mg or placebo via subcutaneous injection every six months for a total duration of 52 weeks, maintaining their existing asthma therapies throughout the study [2].
Clinicians should consult current prescribing information for full dosing guidance.

The primary endpoint was the annualized rate of asthma exacerbations requiring medical intervention, highlighting the drug's efficacy in managing severe asthma exacerbations [2].

What This Means for Clinical Practice

Depemokimab provides a new option for clinicians treating patients with severe eosinophilic asthma, particularly those who have not achieved adequate control with existing therapies. The biannual injection schedule may enhance patient adherence and reduce the burden of daily medication regimens. Clinicians should consider this therapy for patients with a confirmed eosinophilic phenotype who continue to experience exacerbations despite optimized treatment. The integration of depemokimab into clinical practice could lead to improved asthma control and a reduction in exacerbation rates, ultimately enhancing patient outcomes and quality of life. As further data become available, understanding its long-term safety and effectiveness will be crucial in informing treatment decisions.

Clinical Perspective

Workflow: Clinicians should evaluate patients for eosinophilic phenotype and consider depemokimab as an add-on therapy.

Economics: The introduction of a new injectable therapy may impact healthcare costs related to asthma management.

Patient Outcomes: Improved control of asthma symptoms could lead to enhanced quality of life for patients with severe asthma.

Dr. Nikhil Chatterjee, Pulmonology

FDA Approves Depemokimab for Severe Asthma: Eosinophilic Phenotype Treatment

Executive Brief

Key Data at a Glance

Clinical Context

Key Findings

What This Means for Clinical Practice

Clinical Perspective

References

Related Articles

Severe Asthma Biologics: Mepolizumab, Benralizumab, Dupilumab, Tezepelumab, and Depemokimab Insights for 2025

Verified HCP Portal